Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bioventus Inc.BVS · Entity 4996 | Director · 10% owner | June 02, 2026 | June 04, 2026 |
| MIMEDX GROUP, INC.MDXG · Entity 5271 | Director · 10% owner | July 02, 2020 | August 28, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bioventus Inc.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 117,523 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Exercise / conversion · Acquired 32,282 · Balance 117,523 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-02 · Exercise / conversion · Disposed 32,282 · Balance 0 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3: The RSUs vested on June 2, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 25,146 |
Reported balance
After 2026-06-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-03 · Grant · Acquired 25,146 · Balance 25,146 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F4: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee Footnote | 13,021,324 |
Reported balance
Holding disclosure · report date 2026-06-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 13,021,324 F1: Includes 12,096,702 shares of Class A Common Stock held by EW Healthcare Partners Acquisition Fund, L.P. ("Essex Stockholder") and 924,622 shares of Class A Common Stock held by White Pine Medical, LLC ("White Pine"). EW Healthcare Partners Acquisition Fund UGP, LLC ("General Partner") is the general partner of EW Healthcare Partners Acquisition Fund GP, L.P., which is the general partner of Essex Stockholder, which is the managing member of White Pine. Messrs. Sutter, Vainio, Eastman, and Barry (collectively, the "Managers") are the managers of the General Partner. The Managers disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 12,096,702 shares of Class A Common Stock held by EW Healthcare Partners Acquisition Fund, L.P. ("Essex Stockholder") and 924,622 shares of Class A Common Stock held by White Pine Medical, LLC ("White Pine"). EW Healthcare Partners Acquisition Fund UGP, LLC ("General Partner") is the general partner of EW Healthcare Partners Acquisition Fund GP, L.P., which is the general partner of Essex Stockholder, which is the managing member of White Pine. Messrs. Sutter, Vainio, Eastman, and Barry (collectively, the "Managers") are the managers of the General Partner. The Managers disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F3: The RSUs vested on June 2, 2026.
F4: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.
MIMEDX GROUP, INC.
Report date July 02, 2020 · Filed August 28, 2020 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series B Preferred Stock, par value $.001 per shareSEC Table I · non-derivative | IndirectFund | 23,376,623 |
Reported balance
Holding disclosure · report date 2020-07-02 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 23,376,623 F1: The Series B Convertible Preferred Stock (the "Shares") of MiMedx Group, Inc. (the "Company") reported herein were acquired by Falcon Fund 2 Holding Company, L.P., a Delaware limited partnership (the "Fund") on July 2, 2020. The Fund is managed by EW Healthcare Partners Fund 2-UGP, LLC, its general Partner ("EWHP"). EWHP, in its capacity as the investment manager of the Fund, has the power to vote and the power to direct the disposition of all Shares held by the Fund. Accordingly, EWHP may be deemed to beneficially own shares of common stock of the Company issuable upon conversion of the Shares (the "Common Stock"). The reporting person disclaims beneficial ownership of the Shares reported herein except to the extent of the reporting person's pecuniary interest therein. F2: The Fund has the right, at its option, to convert its Shares, in whole or in part, into a number of fully paid and non-assessable shares of Common Stock equal to the Purchase Price Per Share ($1,000), plus any accrued and unpaid dividends divided by $3.85 (the "Conversion Price"), provided that such conversion does not result in the Fund, together with its affiliates, holding more than 19.9% of the votes entitled to be cast at any stockholders meeting or beneficially owning in excess of 19.9% of the then-outstanding shares of Common Stock (the "Beneficial Ownership Cap"). F3: The Shares (including any accrued and unpaid dividends) will, subject to the Beneficial Ownership Cap, automatically convert into Common Stock at any time after July 2, 2023, provided that the Common Stock has traded at 200% or more of the Conversion Price for 20 out of 30 consecutive trading days and as of the close of trading on the trading day immediately prior to the date of conversion, the Common Stock has traded at 200% or more of the Conversion Price. To the extent any Shares cannot be converted due to operation of the Beneficial Ownership Cap, it shall remain outstanding and automatically convert at such time as such conversion would be permitted under the Beneficial Ownership Cap. F4: Martin P. Sutter is one of several managers of EWHP (the "Managers"). Each of the Managers may be deemed to exercise shared voting and investment power with respect to the Shares. Each of EWHP and the Managers, including Mr. Sutter who is a member of the Company's board of directors, disclaims beneficial ownership of the shares held by the Fund, except to the extent of any pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSpouse | 500 |
Reported balance
Holding disclosure · report date 2020-07-02 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance 500 F5: This amendment is filed to correct a typographical error which incorrectly attributed 500 shares to the wrong director. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series B Convertible Preferred Stock (the "Shares") of MiMedx Group, Inc. (the "Company") reported herein were acquired by Falcon Fund 2 Holding Company, L.P., a Delaware limited partnership (the "Fund") on July 2, 2020. The Fund is managed by EW Healthcare Partners Fund 2-UGP, LLC, its general Partner ("EWHP"). EWHP, in its capacity as the investment manager of the Fund, has the power to vote and the power to direct the disposition of all Shares held by the Fund. Accordingly, EWHP may be deemed to beneficially own shares of common stock of the Company issuable upon conversion of the Shares (the "Common Stock"). The reporting person disclaims beneficial ownership of the Shares reported herein except to the extent of the reporting person's pecuniary interest therein.
F2: The Fund has the right, at its option, to convert its Shares, in whole or in part, into a number of fully paid and non-assessable shares of Common Stock equal to the Purchase Price Per Share ($1,000), plus any accrued and unpaid dividends divided by $3.85 (the "Conversion Price"), provided that such conversion does not result in the Fund, together with its affiliates, holding more than 19.9% of the votes entitled to be cast at any stockholders meeting or beneficially owning in excess of 19.9% of the then-outstanding shares of Common Stock (the "Beneficial Ownership Cap").
F3: The Shares (including any accrued and unpaid dividends) will, subject to the Beneficial Ownership Cap, automatically convert into Common Stock at any time after July 2, 2023, provided that the Common Stock has traded at 200% or more of the Conversion Price for 20 out of 30 consecutive trading days and as of the close of trading on the trading day immediately prior to the date of conversion, the Common Stock has traded at 200% or more of the Conversion Price. To the extent any Shares cannot be converted due to operation of the Beneficial Ownership Cap, it shall remain outstanding and automatically convert at such time as such conversion would be permitted under the Beneficial Ownership Cap.
F4: Martin P. Sutter is one of several managers of EWHP (the "Managers"). Each of the Managers may be deemed to exercise shared voting and investment power with respect to the Shares. Each of EWHP and the Managers, including Mr. Sutter who is a member of the Company's board of directors, disclaims beneficial ownership of the shares held by the Fund, except to the extent of any pecuniary interests therein.
F5: This amendment is filed to correct a typographical error which incorrectly attributed 500 shares to the wrong director.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABIOMED INC
Report date December 22, 2022 · Filed December 27, 2022
Section 16 reporting ended · disclosed 2022-12-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 1
1 source rowRow 1 · 2022-12-22 · Disposition to issuer · Disposed 123,370 · Balance 0 F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share. F3: Reflects the correction of an immaterial error in the balance reported in the reporting person's Form 4 filed on November 17, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement.
F2: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share.
F3: Reflects the correction of an immaterial error in the balance reported in the reporting person's Form 4 filed on November 17, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 4, 2026 20:48 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 25,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001017832-26-000002 · wk-form4_1780606079.xml · derivative · entry 4 SUTTER MARTIN P · CIK 0001017832 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,146 Underlying: Class A Common Stock · 25,146 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F4 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F4 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:48 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 32,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001017832-26-000002 · wk-form4_1780606079.xml · derivative · entry 3 SUTTER MARTIN P · CIK 0001017832 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 32,282 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs vested on June 2, 2026. F3 · derivative.expiration_date: The RSUs vested on June 2, 2026. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:48 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 32,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001017832-26-000002 · wk-form4_1780606079.xml · nonDerivative · entry 1 SUTTER MARTIN P · CIK 0001017832 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 01:30 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 32,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000310 · wk-form4_1749087044.xml · derivative · entry 4 SUTTER MARTIN P · CIK 0001017832 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,282 Underlying: Class A Common Stock · 32,282 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F4 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F4 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 01:30 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 26,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000310 · wk-form4_1749087044.xml · derivative · entry 3 SUTTER MARTIN P · CIK 0001017832 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 26,493 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs vested on June 2, 2025. F3 · derivative.expiration_date: The RSUs vested on June 2, 2025. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 01:30 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 26,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000310 · wk-form4_1749087044.xml · nonDerivative · entry 1 SUTTER MARTIN P · CIK 0001017832 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:28 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 26,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000291 · wk-form4_1718314129.xml · derivative · entry 1 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,493 Underlying: Class A Common Stock · 26,493 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F2 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 07, 2024 Filed Jun 12, 2024 00:47 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 30,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000272 · wk-form4_1718153235.xml · derivative · entry 3 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 30,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs vested on June 7, 2024. F3 · derivative.expiration_date: The RSUs vested on June 7, 2024. Read SEC document |
| June 07, 2024 Filed Jun 12, 2024 00:47 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 30,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000272 · wk-form4_1718153235.xml · nonDerivative · entry 1 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2023 Filed Jun 13, 2023 21:12 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 30,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000046 · primary_doc.xml · derivative · entry 4 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,400 Underlying: Class A Common Stock · 30,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F4 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F4 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 06, 2023 Filed Jun 13, 2023 21:12 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 16,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000046 · primary_doc.xml · derivative · entry 3 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 16,648 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs vested on June 6, 2023. F3 · derivative.expiration_date: The RSUs vested on June 6, 2023. Read SEC document |
| June 06, 2023 Filed Jun 13, 2023 21:12 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 16,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000046 · primary_doc.xml · nonDerivative · entry 1 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 20:47 UTC | ABIOMED INC NASD · Entity 121309 | Disposition to issuerCommon Stock, $0.01 par value | 123,370 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-013033 · form4-12282022_011240.xml · nonDerivative · entry 1 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2 · kind: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share. F1 · shares: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2 · shares: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share. F3 · shares: Reflects the correction of an immaterial error in the balance reported in the reporting person's Form 4 filed on November 17, 2022. F1 · price: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2 · price: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 16:05 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 141 | $375.56 | $52,954.12 |
DisclosureSEC source: 0001415889-22-011489 · form4-11172022_091121.xml · nonDerivative · entry 4 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,370 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F5 · price: This price represents the sale price of the transactions on the reported date at $375.5611. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 16:05 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 1,859 | $374.66 | $696,496.10 |
DisclosureSEC source: 0001415889-22-011489 · form4-11172022_091121.xml · nonDerivative · entry 3 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,511 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F4 · price: This price represents the sale price of the transactions on the reported date at $374.6617. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 16:05 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 867 | $374.92 | $325,059.02 |
DisclosureSEC source: 0001415889-22-011489 · form4-11172022_091121.xml · nonDerivative · entry 2 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,370 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F3 · price: This price represents the sale price of the transactions on the reported date at $374.9239. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 16:05 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 1,133 | $374.18 | $423,949.11 |
DisclosureSEC source: 0001415889-22-011489 · form4-11172022_091121.xml · nonDerivative · entry 1 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,237 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F2 · price: This price represents the sale price of the transactions on the reported date at $374.1828. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 17:09 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 20 | $287.44 | $5,748.80 |
DisclosureSEC source: 0001415889-22-008776 · form4-08172022_020823.xml · nonDerivative · entry 15 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,839 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F16 · price: This price represents the sale price of the transactions on the reported date at $287.4400. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 17:09 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 78 | $286.49 | $22,346.49 |
DisclosureSEC source: 0001415889-22-008776 · form4-08172022_020823.xml · nonDerivative · entry 14 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,859 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F15 · price: This price represents the sale price of the transactions on the reported date at $286.4935. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 17:09 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 77 | $285.59 | $21,990.11 |
DisclosureSEC source: 0001415889-22-008776 · form4-08172022_020823.xml · nonDerivative · entry 13 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,937 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F14 · price: This price represents the sale price of the transactions on the reported date at $285.5858. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 17:09 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 78 | $284.44 | $22,186.16 |
DisclosureSEC source: 0001415889-22-008776 · form4-08172022_020823.xml · nonDerivative · entry 12 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,014 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F13 · price: This price represents the sale price of the transactions on the reported date at $284.4379. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 17:09 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 205 | $283.51 | $58,118.73 |
DisclosureSEC source: 0001415889-22-008776 · form4-08172022_020823.xml · nonDerivative · entry 11 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,092 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F12 · price: This price represents the sale price of the transactions on the reported date at $283.5060. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 17:09 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 184 | $282.39 | $51,960.46 |
DisclosureSEC source: 0001415889-22-008776 · form4-08172022_020823.xml · nonDerivative · entry 10 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,297 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F11 · price: This price represents the sale price of the transactions on the reported date at $282.3938. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 17:09 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 785 | $281.52 | $220,990.45 |
DisclosureSEC source: 0001415889-22-008776 · form4-08172022_020823.xml · nonDerivative · entry 9 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,481 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F10 · price: This price represents the sale price of the transactions on the reported date at $281.5165. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 17:09 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 573 | $280.59 | $160,775.95 |
DisclosureSEC source: 0001415889-22-008776 · form4-08172022_020823.xml · nonDerivative · entry 8 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,266 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F9 · price: This price represents the sale price of the transactions on the reported date at $280.5863. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 17:09 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 82 | $293.44 | $24,062.11 |
DisclosureSEC source: 0001415889-22-008776 · form4-08172022_020823.xml · nonDerivative · entry 7 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,839 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F8 · price: This price represents the sale price of the transactions on the reported date at $293.4404. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 17:09 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 145 | $292.47 | $42,408.32 |
DisclosureSEC source: 0001415889-22-008776 · form4-08172022_020823.xml · nonDerivative · entry 6 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,921 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · price: This price represents the sale price of the transactions on the reported date at $292.4712. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 17:09 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 840 | $291.33 | $244,721.15 |
DisclosureSEC source: 0001415889-22-008776 · form4-08172022_020823.xml · nonDerivative · entry 5 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,066 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · price: This price represents the sale price of the transactions on the reported date at $291.3347. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 17:09 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 483 | $290.60 | $140,360.48 |
DisclosureSEC source: 0001415889-22-008776 · form4-08172022_020823.xml · nonDerivative · entry 4 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,906 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F5 · price: This price represents the sale price of the transactions on the reported date at $290.6014. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 17:09 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 114 | $289.63 | $33,017.67 |
DisclosureSEC source: 0001415889-22-008776 · form4-08172022_020823.xml · nonDerivative · entry 3 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,389 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F4 · price: This price represents the sale price of the transactions on the reported date at $289.6287. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 17:09 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 285 | $288.44 | $82,203.98 |
DisclosureSEC source: 0001415889-22-008776 · form4-08172022_020823.xml · nonDerivative · entry 2 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,503 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F3 · price: This price represents the sale price of the transactions on the reported date at $288.4350. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 17:09 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 51 | $287.66 | $14,670.81 |
DisclosureSEC source: 0001415889-22-008776 · form4-08172022_020823.xml · nonDerivative · entry 1 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,788 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F2 · price: This price represents the sale price of the transactions on the reported date at $287.6629. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 11, 2022 Filed Aug 12, 2022 16:15 UTC | ABIOMED INC NASD · Entity 121309 | Tax withholdingCommon Stock, $0.01 par value | 232 | $293.34 | $68,054.88 |
DisclosureSEC source: 0001415889-22-008538 · form4-08122022_010820.xml · nonDerivative · entry 2 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,839 F2 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F2 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 16:15 UTC | ABIOMED INC NASD · Entity 121309 | GrantCommon Stock, $0.01 par value | 681 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-008538 · form4-08122022_010820.xml · nonDerivative · entry 1 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,071 F1 · kind: Represents shares underlying the grant of restricted stock units that are to be settled in common stock upon vesting. The restricted stock units will vest in full on the earlier of: (a) the first anniversary of the date of grant; and (b) the date of the Corporation's 2023 Annual Meeting; that such awards shall be subject to a Time-Based Restricted Stock Unit Award Agreement in accordance with the Second Amended & Restated 2015 Omnibus Incentive Plan F1 · shares: Represents shares underlying the grant of restricted stock units that are to be settled in common stock upon vesting. The restricted stock units will vest in full on the earlier of: (a) the first anniversary of the date of grant; and (b) the date of the Corporation's 2023 Annual Meeting; that such awards shall be subject to a Time-Based Restricted Stock Unit Award Agreement in accordance with the Second Amended & Restated 2015 Omnibus Incentive Plan Read SEC document |
| June 17, 2022 Filed Jun 23, 2022 00:38 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 16,648 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023638 · doc4.xml · derivative · entry 1 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,648 Underlying: Class A Common Stock · 16,648 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date. F2 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| May 18, 2022 Filed May 19, 2022 16:49 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 15 | $253.22 | $3,798.30 |
DisclosureSEC source: 0001415889-22-005316 · form4-05192022_010549.xml · nonDerivative · entry 18 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,390 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F19 · price: This price represents the sale price of the transactions on the reported date at $253.2200. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer Read SEC document |
| May 18, 2022 Filed May 19, 2022 16:49 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 103 | $251.85 | $25,940.67 |
DisclosureSEC source: 0001415889-22-005316 · form4-05192022_010549.xml · nonDerivative · entry 17 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,405 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F18 · price: This price represents the sale price of the transactions on the reported date at $251.8512. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 18, 2022 Filed May 19, 2022 16:49 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 155 | $250.82 | $38,876.87 |
DisclosureSEC source: 0001415889-22-005316 · form4-05192022_010549.xml · nonDerivative · entry 16 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,508 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F17 · price: This price represents the sale price of the transactions on the reported date at $250.8185. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 18, 2022 Filed May 19, 2022 16:49 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 167 | $249.75 | $41,707.43 |
DisclosureSEC source: 0001415889-22-005316 · form4-05192022_010549.xml · nonDerivative · entry 15 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,663 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F16 · price: This price represents the sale price of the transactions on the reported date at $249.7451. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 18, 2022 Filed May 19, 2022 16:49 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 22 | $247.59 | $5,447.09 |
DisclosureSEC source: 0001415889-22-005316 · form4-05192022_010549.xml · nonDerivative · entry 14 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,830 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F15 · price: This price represents the sale price of the transactions on the reported date at $247.5948. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 18, 2022 Filed May 19, 2022 16:49 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 166 | $246.78 | $40,964.98 |
DisclosureSEC source: 0001415889-22-005316 · form4-05192022_010549.xml · nonDerivative · entry 13 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,852 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F14 · price: This price represents the sale price of the transactions on the reported date at $246.7770. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 18, 2022 Filed May 19, 2022 16:49 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 155 | $245.66 | $38,078.00 |
DisclosureSEC source: 0001415889-22-005316 · form4-05192022_010549.xml · nonDerivative · entry 12 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,018 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F13 · price: This price represents the sale price of the transactions on the reported date at $245.6645. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 18, 2022 Filed May 19, 2022 16:49 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 189 | $244.32 | $46,175.65 |
DisclosureSEC source: 0001415889-22-005316 · form4-05192022_010549.xml · nonDerivative · entry 11 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,173 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F12 · price: This price represents the sale price of the transactions on the reported date at $244.3156. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 18, 2022 Filed May 19, 2022 16:49 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 155 | $242.77 | $37,629.92 |
DisclosureSEC source: 0001415889-22-005316 · form4-05192022_010549.xml · nonDerivative · entry 10 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,362 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F11 · price: This price represents the sale price of the transactions on the reported date at $242.7737. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 18, 2022 Filed May 19, 2022 16:49 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 200 | $241.84 | $48,368.58 |
DisclosureSEC source: 0001415889-22-005316 · form4-05192022_010549.xml · nonDerivative · entry 9 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,517 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F10 · price: This price represents the sale price of the transactions on the reported date at $241.8429. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 18, 2022 Filed May 19, 2022 16:49 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 398 | $240.68 | $95,791.04 |
DisclosureSEC source: 0001415889-22-005316 · form4-05192022_010549.xml · nonDerivative · entry 8 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,717 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F9 · price: This price represents the sale price of the transactions on the reported date at $240.6810. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 18, 2022 Filed May 19, 2022 16:49 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 275 | $240.07 | $66,019.61 |
DisclosureSEC source: 0001415889-22-005316 · form4-05192022_010549.xml · nonDerivative · entry 7 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,115 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F8 · price: This price represents the sale price of the transactions on the reported date at $240.0713. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 17, 2022 Filed May 19, 2022 16:49 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 10 | $262.18 | $2,621.80 |
DisclosureSEC source: 0001415889-22-005316 · form4-05192022_010549.xml · nonDerivative · entry 6 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,390 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · price: This price represents the sale price of the transactions on the reported date at $262.1800. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 17, 2022 Filed May 19, 2022 16:49 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 38 | $261.55 | $9,939.00 |
DisclosureSEC source: 0001415889-22-005316 · form4-05192022_010549.xml · nonDerivative · entry 5 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,400 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · price: This price represents the sale price of the transactions on the reported date at $261.5526. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 17, 2022 Filed May 19, 2022 16:49 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 304 | $259.15 | $78,781.78 |
DisclosureSEC source: 0001415889-22-005316 · form4-05192022_010549.xml · nonDerivative · entry 4 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,438 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F5 · price: This price represents the sale price of the transactions on the reported date at $259.1506. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.